STOCK TITAN

ClearPoint Neuro (CLPT) Stock News, Mar-May 2021

CLPT NASDAQ

ClearPoint Neuro, Inc. develops and commercializes medical-device and therapy-enabling systems for precise navigation to the brain and spine. Its recurring news includes updates on the FDA-cleared and CE-marked ClearPoint Neuro Navigation System, SmartFrame navigation platform, SmartFlow Neuro Cannula, Velocity Alpha MR High Speed Surgical Drill System, and services that support controlled CNS delivery for cell and gene therapy programs.

Company announcements also cover financial results, product clearances and international regulatory approvals, preclinical development services, biopharma and academic partnerships, and integration of the completed IRRAS Holdings acquisition, which expanded the portfolio into neurocritical care and IRRAflow-related products.

Rhea-AI Summary

ClearPoint Neuro (Nasdaq: CLPT) will present at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 12:00 p.m. Eastern Time. The presentation aims to showcase the company’s advancements in neurological therapies.

The session will be available to watch on-demand for 30 days on ClearPoint Neuro's website, specifically in the Investor Relations section. ClearPoint focuses on delivering therapies for complex neurological disorders using its Navigation System, which has over 4,500 successful procedures and partnerships with over 30 companies in the pharmaceutical and biotechnology sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.90%
Tags
conferences
-
Rhea-AI Summary

ClearPoint Neuro has announced the first human cases using its SmartFrame Array Neuro Navigation System, aiming to enhance neurosurgery workflows by reducing procedure times in MRI and Operating Room settings. The Array system's flexibility is expected to increase accessibility for hospitals and surgeons. Initial procedures were conducted by prominent neurosurgeons at renowned institutions, showcasing the system's efficiency. Full market release of the Array is anticipated in early 2022, following a phase of limited market release to gather training materials and case studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Summary

ClearPoint Neuro reported Q1 2021 revenue of $4.0 million, up 29% year-over-year. Biologics and drug delivery revenue surged 61% to $1.7 million. The company added new partnerships, raising its total to approximately 30. Case volume increased to 214, exceeding previous estimates. Following a public offering, net proceeds reached $46.8 million, bolstering cash reserves to nearly $65.0 million. Despite hospital budget constraints, the company anticipates 2021 revenues between $16.0 million and $17.5 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
Rhea-AI Summary

ClearPoint Neuro (Nasdaq: CLPT) announced a partnership with D&K Engineering to develop a robotic system for MRI and operating room use. This collaboration aims to streamline neurosurgery, enhancing procedural efficiency and patient interaction. The partnership leverages ClearPoint's existing technology and D&K's expertise in medical devices. The robotic system is expected to see its first clinical application in 2023. ClearPoint Neuro's platform has FDA clearance and is already implemented in over 60 clinical sites across the U.S., Canada, and Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
partnership
-
Rhea-AI Summary

ClearPoint Neuro (Nasdaq: CLPT) announced its Q1 2021 financial results release date set for May 11, 2021, after market close. The live broadcast for the results will occur at 4:30 PM ET on the same day. Interested parties can access the call online or by phone. ClearPoint Neuro focuses on improving patient quality of life through precise therapies for neurological disorders, with FDA-cleared products used in over 60 clinical sites. The company’s partnerships include 25 biologics and drug delivery companies, supporting over 4,000 cases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Summary

ClearPoint Neuro (CLPT) announced its support for Voyager Therapeutics' FDA clearance of the IND application for the gene therapy candidate VY-HTT01, aimed at treating Huntington’s disease, affecting around 30,000 people in the U.S. This gene therapy will undergo a Phase 1/2 clinical trial to assess its safety and tolerability. ClearPoint's navigation and delivery systems play a crucial role in this trial. The company remains committed to innovating and providing clinical services that support complex neurological treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
Rhea-AI Summary

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced on April 23, 2021, that its Board of Directors approved the grant of stock options and restricted shares to Mr. Danilo D’Alessandro. The package includes 30,000 restricted shares and a stock option for 75,000 shares at an exercise price of $5.80, with vesting starting September 29, 2021. This grant follows NASDAQ guidelines and aims to facilitate Mr. D’Alessandro's acceptance of employment. The company focuses on enabling advanced therapies for neurological disorders through its FDA-cleared products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
none
-
Rhea-AI Summary

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announced the upcoming retirement of John N. Spencer, Jr. from its Board of Directors, effective at the Annual Meeting of Stockholders on June 3, 2021. Spencer has served since March 2010 and is credited with substantially contributing to the company's growth. ClearPoint has achieved significant milestones, including nearing its 5,000th case, and holds a preeminent status in the medical device sector. The company provides innovative solutions for neurological disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
none
-
Rhea-AI Summary

ClearPoint Neuro, Inc. (Nasdaq: CLPT) announces that uniQure N.V. has completed patient enrollment for the first dose cohort of a randomized Phase I/II clinical trial of AMT-130 for early-stage Huntington's disease. Six of ten patients received AMT-130 using ClearPoint's navigation systems. A second cohort with 16 patients is set to enroll in late 2021, along with a Phase Ib/II trial planned in Europe. Huntington's disease affects ~70,000 individuals in the U.S. and Europe, with no approved therapies currently available for its progression.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.49%
Tags
Rhea-AI Summary

ClearPoint Neuro (CLPT) announced the appointment of Ellisa Cholapranee as General Counsel, effective April 5, 2021. Reporting to CEO Joe Burnett, Cholapranee brings nearly a decade of legal experience in the life sciences and medical device sectors. Her expertise in compliance, strategy, and partnerships is expected to enhance the company's operations, especially in gene therapy and drug delivery agreements. The company continues to innovate in neurological disorder treatments, with its ClearPoint Neuro Navigation System already installed in over 60 clinical sites.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
management

FAQ

What is the current stock price of ClearPoint Neuro (CLPT)?

ClearPoint Neuro (CLPT) last closed at $7.71.

What is the market cap of ClearPoint Neuro (CLPT)?

The market cap of ClearPoint Neuro (CLPT) is approximately $247.1M.